Abstract 977P
Background
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor globally, Hence, there is an urgent need for safer and more effective options to improve the survival rates of HCC patients. This study aims to evaluate the viability, efficacy, and safety of HAIC and Regorafenib combined with PD-1 inhibitors for treating advanced HCC patients.
Methods
This is a multicenter, randomized controlled clinical study of hepatocellular carcinoma. Eligible individuals with unresectable HCC were randomized into either the HAIC combined with regorafenib and PD-1 inhibitors group (HAIC+REG+ICIs group) or the regorafenib combined with PD-1 inhibitors group (REG+ICIs group). The primary endpoint is the objective response rate (ORR). Secondary endpoints include PFS, OS, DCR (all assessed by BICR per RECIST v1.1), and safety.
Results
Up to April 24, 2023, a total of 45 patients were enrolled and all patients are available for analysis. The HAIC+REG+ICIs group and the REG+ICIs group included 28 and 17 patients, respectively.The median age were 52.5 years (range, 32-68) and 47.0 years (range, 24-79), 92.9% and 94.1% were male for each group, the proportions of child-pugh A/B were 64.3%/35.7% vs. 88.2%/11.8%; and the patients with China Liver Cancer Staging (CNLC) Ib/IIa/IIb/IIIa/IIIb/IV stage were 0.0%/3.6%/35.7%/21.4%/32.1%/7.1% vs. 5.9%/11.8%/47.1%/11.8%/17.6%/5.9%, respectively. All patients were infected with HBV. The median follow-up time was 16.6 months (1-21.2). The ORR was 39.3% (11/28) and 29.4%(5/17) for HAIC+REG+ICIs group and the REG+ICIs group, P=0.502. DCR was 82.1%(23/28) and 52.9%(9/17) respectively, P=0.036. The median OS of HAIC+REG+ICIs group was significant longer than REG+ICIs group (19.1 vs. NA months, P=0.03; HR=0.039 95% CI: 0.101-0.941). This study is currently ongoing.
Conclusions
HAIC combined with Regorafenib and PD-1 inhibitors compared with Regorafenib and PD-1 inhibitors showed a better tumor response rate, but there was no significant difference. However HAIC combined with regorafenib and PD-1 inhibitors can significantly prolong the overall survival of second-line HCC patients.
Clinical trial identification
ChiCTR2100046555.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18